Presentation is loading. Please wait.

Presentation is loading. Please wait.

Malignant diseases of the bone marrow Tornóci László Semmelweis University Institute of Pathophysiology.

Published byCorey Norris Modified over 8 years ago

Similar presentations

Presentation on theme: "Malignant diseases of the bone marrow Tornóci László Semmelweis University Institute of Pathophysiology."— Presentation transcript:

1 Malignant diseases of the bone marrow Tornóci László Semmelweis University Institute of Pathophysiology

2 Malignancies granulocytic, monocytic, erythroid, megakaryocytic MyeloidLymphoid malignant lymphomas REAL classification

3 Classification of myeloid malignancies Chronic myeloproliferative diseases Myelodysplastic syndromes Acute myeloid leukemias FAB (old)WHO (new) Chronic myeloproliferative diseases Myelodysplastic/myeloproliferative diseases Myelodysplastic syndromes Acute myeloid leukemias

4 Chronic myeloproliferative diseases CML Ph+ and Ph- Chronic idiopathic myelofibrosis Polycythemia vera Essential thrombocytemia FAB (old)WHO (new) CML Ph+ Chronic neutrophilic leukemia Chronic eosinophilic leukemia/hypereosinophilic syndrome Chronic idiopathic myelofibrosis Polycythemia vera Essential thrombocytemia

5 Myelodysplastic/myeloproliferative diseases none FAB (old)WHO (new) Atypical myelogenous leukemia (aCML) Chronic myelomonocytic leukemia (CMML) Juvenile myelomonocytic leukemia (JMML)

6 Myelodysplastic syndromes Refractory anemia (RA) Refractory anemia with ringed sideroblasts (RARS) Refractory anemia with excess blasts (RAEB) Refractory anemia with excess blasts in transformation (RAEB-T) Chronic myelomonocytic leukemia (CMML) FAB (old)WHO (new) Refractory anemia with ringed sideroblasts (FAB: RARS) without ringed sideroblasts (FAB: RA) Refractory cytopenia with multilineage dysplasia (new) Refractory anemia with excess blasts (FAB: RAEB) 5q- syndrome (new) unclassifiable (new)

7 Acute myeloid leukemias M0: minimally differentiated M1: myeloblastic leukemia without maturation M2: myeloblastic leukemia with maturation M3: hypergranular promyelocytic leukemia M4: myelomonocytic leukemia M4Eo: variant, increase in marrow eosinophils M5: monocytic leukemia M6: erythroleukemia (DiGuglielmo's disease) M7: megakaryoblastic leukemia FAB (old)WHO (new) AML with recurrent cytogenetic translocations AML with multilineage dysplasia AML with myelodysplastic syndrome, therapy related AML not otherwise categorized (Outlined only!)

Download ppt "Malignant diseases of the bone marrow Tornóci László Semmelweis University Institute of Pathophysiology."

Similar presentations

The WHO Classification of Hematological Malignancies

The WHO Classification of Hematological Malignancies
Week 10: Leukemia AML ALL FAB classification WHO classification

Week 10: Leukemia AML ALL FAB classification WHO classification
איכילוב 7 46y female WBC=62.000\ul Hb=16.1g% Normal indices

איכילוב 7 46y female WBC=62.000\ul Hb=16.1g% Normal indices
MALIGNANCIES OF THE HAEMAPOIETIC STEM CELL. Haemapoietic Stem Cell are pluripotent and give rise to all of the haemopoietic cell under the action of cytokines.

MALIGNANCIES OF THE HAEMAPOIETIC STEM CELL. Haemapoietic Stem Cell are pluripotent and give rise to all of the haemopoietic cell under the action of cytokines.
Coding Haematological Malignancies in Cancer Registries part I : Myeloid malignancies Pr Marc Maynadié Registre des Hémopathies Malignes de Côte d'Or Faculté.

Coding Haematological Malignancies in Cancer Registries part I : Myeloid malignancies Pr Marc Maynadié Registre des Hémopathies Malignes de Côte d'Or Faculté.
Leukemia John H. Ward, MD Professor of Medicine Chief, Oncology Division Department of Internal Medicine University of Utah School of Medicine Huntsman.

Leukemia John H. Ward, MD Professor of Medicine Chief, Oncology Division Department of Internal Medicine University of Utah School of Medicine Huntsman.
NEOPLASTIC DISORDERS OF THE BONE MARROW

NEOPLASTIC DISORDERS OF THE BONE MARROW
Myelodysplastic syndromes Achievements in understanding and treatment prof. dr hab. med. Krzysztof Lewandowski.

Myelodysplastic syndromes Achievements in understanding and treatment prof. dr hab. med. Krzysztof Lewandowski.
Leukocytes 4-10 000/mm3 Differential count: neutrophils 60- 70%, eosinophils 2-4% basophils - up to 1% ly: 20 – 30%, mono 3-8% ↓ Leukopenias most often:

Leukocytes /mm3 Differential count: neutrophils %, eosinophils 2-4% basophils - up to 1% ly: 20 – 30%, mono 3-8% ↓ Leukopenias most often:
Myelodysplastic Syndrome

Myelodysplastic Syndrome
Myelodysplastic Syndrome

Myelodysplastic Syndrome
Introduction to Leukemia

Introduction to Leukemia
Week 12: Myelodysplastic Syndrome

Week 12: Myelodysplastic Syndrome
FAB Classification (French, American, British)

FAB Classification (French, American, British)
Myelodysplastic syndrome and acute myeloid leukaemia

Myelodysplastic syndrome and acute myeloid leukaemia
WHO CLASSIFICATION OF MYELOID NEOPLASMS 2000  Chronic myeloproliferative disorders (CMPD)  Myelodysplastic / myeloproliferative diseases (MDS/MPD) 

WHO CLASSIFICATION OF MYELOID NEOPLASMS 2000  Chronic myeloproliferative disorders (CMPD)  Myelodysplastic / myeloproliferative diseases (MDS/MPD) 
HEMATOLOGIC MALIGNANCIES Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic.

HEMATOLOGIC MALIGNANCIES Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic.
Lymphomas & Leukemias General Pathology Histogenetic Classification

Lymphomas & Leukemias General Pathology Histogenetic Classification
Acute Myeloid Leukemias (AML)

Acute Myeloid Leukemias (AML)
Myelodysplastic syndrome overview Razelle Kurzrock Seminars in Haematology, Vol 39, No 3, Suppl 2 (July) 2002, pp 18-25.

Myelodysplastic syndrome overview Razelle Kurzrock Seminars in Haematology, Vol 39, No 3, Suppl 2 (July) 2002, pp

Similar presentations

Ads by Google